Biometrics, Biotech and my Vans are firing

And the "Perfect" Election Strategy ☑️                                                                                                                                                                                                                                                                                                                                                                                                                 October 29, 2024 | [Read Online]( And the "Perfect" Election Strategy ☑️ *Sponsored by Oxford Club and Adam Mesh Live Good day, 360! Just a quick reminder the “Perfect Election Strategy” is happening right around the corner (2pm EST) - [reserve your front row seat here]( ☑️. FOCUS LIST🔎 BKYI - Up over 100% in the pre-market after announcing it has secured $910,000 order to upgrade long-time financial services customer to enhanced biometric customer identification technology SHPH - Up over 50% in pre after announcing it has completed clinical trial site enrollment for Phase 2 of Ropidoxuridine for treatment of patients with Glioblastoma VFC - Up over 19% in pre after Vans owner beats earnings, issues improved guidance *Sponsored by Oxford Club What if Trump wins? What about Kamala? Will this affect my trading? TODAY AT 2EST [We’ll address all your questions at first-ever election event with “election-pro” Alexander Green.]( HOTLIST🔥 BKYI - Up over 100% in the pre-market after announcing it has secured $910,000 order to upgrade long-time financial services customer to enhanced biometric customer identification technology BIO-key International Inc. (BKYI) develops and markets fingerprint identification biometric technology and software solutions, and enterprise-ready identity access management solutions for commercial, government, and education customers in the United States and internationally. In the pre-market this morning, [the company announced]( that it has received a $910,000 order from a long-term financial services customer to upgrade to BIO-key’s “fingerprint only” Biometric Customer Identification Technology. The technology enhancement builds on the customer’s expanding deployment of BIO-key technology to verify the identity of customers, now totaling over 25 million enrolled individuals.  Previously customers were verified at a branch location by matching their fingerprint scan and their ID number, account number or card. By upgrading to BIO-key’s “fingerprint only” identification, the customer will be able to identify each of its clients by a simple fingerprint scan – without the need for a card, account or ID number, saving an estimated thirty seconds per client encounter.\ Shares of BKYI traded up over 100% in the pre-market in reaction to the news. The $1.22 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $1.34, $1.40, $1.50 and then the pre-market high at $1.54. Beyond that, $1.68, $1.95, $2.12, $2.50 and $3.10 come into play. Below $1.22, targets to the downside are $1, $0.82 and then a gap fill at $0.69. SHPH - Up over 50% in pre after announcing it has completed clinical trial site enrollment for Phase 2 of Ropidoxuridine for treatment of patients with Glioblastoma Shuttle Pharmaceuticals Holdings Inc. (SHPH) is a clinical stage pharmaceutical company that develops novel therapies to cure cancers. In the after-hours yesterday, [the company announced]( it has finalized agreements with all six of the planned site enrollment locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma following the entry into agreements with Georgetown University Medical Center and UNC Medical Center. Patients are currently undergoing screening for enrollment in the trial. Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure. Shuttle has received Orphan Drug Designation from the FDA for IPdR, providing potential marketing exclusivity upon first FDA approval for treatment of the disease. Shares of SHPH traded up over 50% in the pre-market in reaction to the news. The $2 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $2.20, $2.30 and then the pre-market high at $2.40. Beyond that, targets to the upside are $2.50, $2.76 and then $3.30 above that. Below $2, targets to the downside are $1.90, $1.85, $1.60, $1.50 and then a gap fill at $1.33. *Together with Adam Mesh Live Recognize This Guy? (Not Leno, the other guy!) Join long-time Trader, Adam Mesh & Jeff Bishop LIVE to talk everything OPTIONS  [Wednesday, October 30th at 1:00pm EST HERE]( Adam’s been a trader for over 20+ years, has been on Jay Leno, Fox Business, and has had his OWN reality show! Both are SUCKERS for options and trade them differently, so mark your calendars and don’t miss this FIRST-TIME event 💥 [BE HERE WED 1PM EST]( VFC - Up over 19% in pre after Vans owner beats earnings, issues improved guidance V.F. Corporation (VFC) together with its subsidiaries, engages in the design, procurement, marketing, and distribution of branded lifestyle apparel, footwear, and accessories for men, women, and children in the Americas, Europe and internationally. It is the parent company of brands The North Face and Vans. In the after-hours yesterday, [the company issued]( Q2 2025 earnings and issued forward guidance. Highlights include: Adjusted EPS of $0.60 for Q2 vs analyst estimate of $0.38. Revenue came in at $2.76 billion vs consensus estimate of $2.73 billion, though down 6% YoY. The company's gross margin improved by 120 basis points to 52.2% compared to the same period last year. Looking ahead, VF Corp provided guidance for the third quarter, projecting revenue between $2.7 billion and $2.75 billion, representing a 1% to 3% YoY decline. This outlook is slightly below the analyst consensus of $2.77 billion. The also stated “we are on track to reach our previously announced $300 million savings target by the end of FY25." Shares of VFC traded up over 19% in the pre-market in reaction to the news. The first target for bulls is the after-hours high at $20.95. Beyond that, targets to the upside are $21.40, $22, $22.63, $23 and then $23.50. Below $20.95, targets to the downside are $20, $19.50, $19.18, $18.15, $17.50 and $17.03. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](